Sepin-1 is a first-in-class, orally-available, small molecule inhibitor of Separase. Separase induces aneuploidy, genomic instability, tumorigenesis, and intratumor heterogeneity. Separase overexpression strongly correlates with high incidence of relapse, metastasis, and a lower 5-year overall survival rate.
Effective in preclinical models – Sepin-1 is efficacious in vivo against difficult-to-treat tumors such as TNBC and other HER2-negative cancers.
Encouraging safety data –IND-enabling studies conducted on Sepin-1 suggest the compound safe in pharmacologically active doses
Available for commercial development –Sepin Biotech has access to patents with claims covering all fields of use for Sepin-1. These fields of use are unencumbered and available for third-party development opportunities.
Sepin Biotech is currently developing Sepin-1 as a therapy for breast cancer in patients’ human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.